KRAS and metastatic malignant neoplasm: This knowledge will promote a phylogenetic-based SIAH-centered drug design toward generating useful SIAH-specific peptides and SIAH small molecule inhibitors as new and more efficacious therapeutics to eradicate oncogenic K-RAS-driven metastatic cancer in the future.